S
Shogo Kumagai
Publications - 7
Citations - 201
Shogo Kumagai is an academic researcher. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 1, co-authored 1 publications receiving 25 citations.
Papers
More filters
Journal ArticleDOI
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
Shogo Kumagai,Shohei Koyama,Kota Itahashi,Tokiyoshi Tanegashima,Yi-Tzu Lin,Yosuke Togashi,Takahiro Kamada,Takuma Irie,Genki Okumura,Hidetoshi Kono,Daisuke Ito,Rika Fujii,Sho Watanabe,Atsuo Sai,Shota Fukuoka,Eri Sugiyama,Gokuran Watanabe,Takuya Owari,Hitomi Nishinakamura,Daisuke Sugiyama,Yuka Maeda,Akihito Kawazoe,Hiroki Yukami,Keigo Chida,Yuuki Ohara,Tatsuya Yoshida,Yuki Shinno,Yuki Takeyasu,Masayuki Shirasawa,Kenta Nakama,Keiju Aokage,Jun Suzuki,Genichiro Ishii,Takeshi Kuwata,Naoya Sakamoto,Masahito Kawazu,Toshihide Ueno,Taisuke Mori,Naoya Yamazaki,Masahiro Tsuboi,Yasushi Yatabe,Takahiro Kinoshita,Toshihiko Doi,Kohei Shitara,Hiroyuki Mano,Hiroyoshi Nishikawa +45 more
TL;DR: In this paper , the balance of programmed death-1 (PD-1)-expressing CD8+ T cells and regulatory T (Treg) cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 blockade therapy through the competition of their reactivation.
Journal ArticleDOI
Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma.
Shogo Kumagai,Masaharu Tashima,Jun Fujikawa,Makoto Iwasaki,Yoshihiro Iwamoto,Yuki Sueki,Akiko Fukunaga,Soshi Yanagita,Momoko Nishikori,Akifumi Takaori-Kondo,Nobuyoshi Arima +10 more
TL;DR: The ALC/AMC ratio before treatment may be a significant prognostic factor predicting PFS of FL, and was shown to be associated with inferior PFS in patients treated with rituximab-containing chemotherapy between 2000 and 2012.
Journal ArticleDOI
BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors
Kota Itahashi,Takuma Irie,Junichiro Yuda,Shogo Kumagai,Tokiyoshi Tanegashima,Yi-Tzu Lin,Sho Watanabe,Yasushi Goto,Jun Suzuki,Keiju Aokage,Masahiro Tsuboi,Yosuke Minami,Genichiro Ishii,Yuichiro Ohe,Wataru Ise,Tomohiro Kurosaki,Yutaka Suzuki,Shohei Koyama,Hiroyoshi Nishikawa +18 more
TL;DR: It is shown that Treg cells in the TME of human lung cancers harbored a completely different open chromatin profile compared with CD8+ T cells, conventional CD4+ T Cells in theTME, and peripheral TReg cells, which can be applied in the development of Treg cell-targeted therapies.
Journal ArticleDOI
Isolation of tumor-infiltrating lymphocytes from preserved human tumor tissue specimens for downstream characterization
TL;DR: Kumagai et al. as discussed by the authors proposed a detailed enzyme-based protocol to isolate tumor-infiltrating lymphocytes (TILs) from human tumor tissues, which was optimized to obtain enough viable TILs from a biopsy tissue specimen for flow cytometrybased TIL immunophenotyping.
Journal ArticleDOI
Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).
Keiju Aokage,Yoshihisa Shimada,Kiyotaka Yoh,Masashi Wakabayashi,Miki Fukutani,Hideki Furuya,Kotaro Nomura,Tomohiro Miyoshi,Kenta Tane,Joji Samejima,Shogo Kumagai,Shohei Koyama,Hiroyoshi Nishikawa,Tetsuro Taki,Takuo Hayashi,Jun Matsubayashi,Genichiro Ishii,Norihiko Ikeda,Masahiro Tsuboi +18 more
TL;DR: In this article , the authors evaluated the efficacy and feasibility of neoadjuvant therapy with pembrolizumab and ramucirumab, a direct vascular endothelial growth factor (VEGF) receptor-2 antagonist, followed by surgery, in patients with PD-L1 positive, clinical stage IB-IIIA NSCLC.